Podcast appearances and mentions of Jennifer Doudna

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

On this episode of The Strategerist, Walter Isaacson, known as one of America's pre-eminent biographies joins host Andrew Kaufmann to discuss some of the world's greatest innovators: Steve Jobs. Elon Musk. Benjamin Franklin. Jennifer Doudna. Albert Einstein. Even Leonardo DaVinci. His most recent work takes a look not at a person, but at a turning point in history: The Greatest Sentence Ever Written, a small but inspiring book that analyzes the second sentence of the Declaration of Independence.

One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.

Episode SummaryIn the Season 2 finale of Breathless, host Jeremie Saunders tackles the ultimate question facing the Cystic Fibrosis (CF) community: Are we finally on the verge of a true cure? Growing up sick, Jeremie developed a psychological "immunity" to the repetitive promise that a cure was "just around the corner." But today, the conversation is fundamentally different.This episode takes us out of the pharmacy and directly into the laboratories where researchers are transitioning from small-molecule symptom management to structural gene editing. Featuring Dr. Bowen Li (University of Toronto), Dr. Paul Eckford (Chief Scientific Officer, CF Canada), and Kelly Grover (CEO, CF Canada), we pull back the curtain on the grueling reality of scientific research—described as "pushing a boulder up a hill with chopsticks." We explore how the global proof of concept from COVID-19 mRNA vaccines has turbocharged CF research, how CRISPR molecular scissors are being engineered to permanently rewrite genetic typos, and how Machine Learning is drastically accelerating the timeline to reach the final 10% of the community.Main Topics & Key Moments1. The Cost of Hope & The Ground ShiftThe Practiced Optimism: Jeremie details the emotional exhaustion of childhood hope cycles, where promised breakthroughs consistently failed to materialize, leading to a defensive "self-preservation" mindset in his twenties.A New Vocabulary: Why current scientific progress is materially different. For the first time, data-driven researchers are using definitive terms like functional cure, mutation-agnostic, and restoring normal function at the source.2. The Grind of the ArchitectureChopsticking the Boulder: Dr. Bowen Li describes the quiet, unglamorous reality of the lab at 8:00 PM on a Tuesday, where progress is measured in microscopic, hard-won inches.The Lazarus Effect vs. The Temped Joy: CEO Kelly Grover recalls an early advocacy trip to Ottawa with a profoundly ill young man, contrasting his miraculous post-Trikafta transformation with the sobering reality of meeting patients who remain devastatingly sick.3. The Molecular Typo: Nonsense MutationsThe Broken Text: While Trikafta acts as a structural prop for a wobbly, misfolded protein, it is entirely useless for patients with "nonsense mutations."The Cellular Stop Sign: Dr. Bowen Li explains that in these rare variations (such as the W57X mutation discussed in previous episodes), the cell hits a premature stop sign in the middle of reading the genetic sentence. The protein is cut off too early and never forms, leaving nothing for modulator drugs to attach to.4. Photocopies and Vaults: mRNA vs. CRISPRThe Vault Analogy: Dr. Li frames human genetics simply: DNA is the master cookbook safely locked inside the nucleus vault. You cannot remove the book, but you can create a temporary photocopy of a single page to take to the kitchen. That photocopy is mRNA.The Platform Revolution: A historical look at mRNA, from its discovery by Brenner and Crick in the 1960s to Katalin Karikó's underfunded, decades-long battle to chemically stabilize the molecule. The global deployment of COVID-19 vaccines served as the ultimate medical proof of concept, opening the floodgates for respiratory disease mapping.The Lipid Nanoparticle Trojan Horse: To get delicate mRNA past the lung's natural "bouncers" (mucus and cilia), scientists wrap it in a micro-engineered fat bubble designed to slide through sticky blockages and hit targeted cells.CRISPR Molecular Scissors: Moving beyond temporary photocopies, CRISPR edits the master cookbook itself. Hijacked from a bacterial immune defense system discovered in yogurt cultures, Jennifer Doudna and Emmanuelle Charpentier engineered the Cas9 protein to act as scissors guided by genetic GPS. Modern iterations—like base editing and prime editing—can cleanly correct a single letter in the double helix without fracturing the strand. Hosted on Acast. See acast.com/privacy for more information.

From robot helpers to smart body parts, the line between human and machine is blurring. This hour, TED speakers design tech that enhances us without diminishing our humanity. Guests include robot choreographer and computer scientist Catie Cuan, engineer and biophysicist Hugh Herr, material scientist Anna Maria Coclite and biochemist Jennifer Doudna.TED Radio Hour+ listeners now get access to bonus episodes, with more ideas from TED speakers and deeper conversations with Manoush. By signing up for Plus, you directly support our work and public media, so all your episodes (like this one!) come to you without sponsor breaks. Learn more at plus.npr.org/ted.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Trevor Martin, Co-Founder and CEO of Mammoth Biosciences, a company at the forefront of next-generation CRISPR technologies. Co-founded alongside Nobel Prize-winning scientist Jennifer Doudna, Mammoth is building a platform to both detect and cure disease by harnessing the natural diversity of CRISPR systems.Trevor's journey into biology was anything but conventional—initially drawn to physics and chemistry, he discovered biology through an interdisciplinary lens that revealed its true complexity and potential for engineering. That shift ultimately led him to Stanford, where he began exploring the intersection of genetics, computation, and real-world impact.From there, this conversation traces the founding of Mammoth, the decision to pursue entrepreneurship over academia, and the ambition to build a generational biotech company—not just a single-asset success. Trevor shares how CRISPR is evolving from a breakthrough technology into a scalable platform capable of addressing a wide range of genetic diseases, with the potential to fundamentally reshape human health.At its core, this episode explores the convergence of science, entrepreneurship, and persistence—highlighting what it takes to translate cutting-edge research into real therapies, and why the next decade of biology may redefine what it means for genetics to determine our future.

What can today's biotech innovators learn from the greatest thinkers in history? In this special episode, we're bringing you a live recording from BIO on the BAYOU featuring a fireside chat between Elaine Hamm, PhD, and Walter Isaacson — renowned biographer of Steve Jobs, Jennifer Doudna, Leonardo da Vinci, Albert Einstein, and other groundbreaking innovators. Together, they explore the power of curiosity, resilience, and imagination in shaping scientific discovery. From the origins of creativity to the ethical challenges of AI and gene editing, this conversation shines a light on the shared traits that drive humanity's boldest breakthroughs. In this episode, you'll learn: Why history's greatest innovators were powered by relentless curiosity — not just intellect. What resilience looks like across centuries, from Leonardo da Vinci to modern-day misfits shaping the future. How scientists, universities, and the public can rebuild trust, communicate science better, and rekindle a shared sense of wonder. Tune in for an inspiring conversation that blends science, storytelling, and the timeless human drive to explore the unknown — straight from the BIO on the BAYOU stage. Links: Connect with Walter Isaacson and check out his new book The Greatest Sentence Ever Written. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

What happened in 1993 still affects medicine today. That was the year women were required to be included in NIH-funded clinical trials, a shift that helped begin correcting decades of male-centered medical research. In this powerful conversation, Sharon Kedar CFA sits down with Jessica Federer, former Chief Digital Officer at Bayer and Managing Director of The Women's Health Fund, to explore why this moment matters not only for women's health, but for human health, innovation, and the future of medicine.They discuss how exclusion from research shaped diagnostics, drug dosing, autoimmune disease, heart health, cancer care, and why one of the world's largest multi-trillion dollar industries still has enormous opportunity ahead.This Episode Is For You If:- You want to understand why women's health impacts everyone- You're curious how clinical trials shape modern medicine- You care about innovation, investing, longevity, and better healthcare outcomesWhat You'll Learn:- Why women were historically excluded from many clinical trials- How 1993 changed medical research standards- Why better science creates better care for everyoneKey Takeaways- Clinical research has historically relied heavily on male data, creating downstream gaps in care.- Including women in research improves diagnostics, treatment, safety, and outcomes across medicine.- Women's health may be one of the greatest innovation opportunities of our time.Connect with Sharon:Connect with Sharon on LinkedIn: https://www.linkedin.com/in/sharonkedar/Learn more about Innovate and Elevate: https:// innovateandelevatepodcast.comSubscribe to Innovate and Elevate on YouTube: https://www.youtube.com/channel/UCuWi1O9RBaPMYuCkKszPYVAJoin the newsletter to receive the latest episodes in your inbox: https://innovateandelevatepodcast.com/emailConnect with Jessica Federer:- Instagram: https://www.instagram.com/jjfeds- LinkedIn: https://www.linkedin.com/in/jessicafederer- TikTok: https://www.tiktok.com/@jessica.federer?_r=1&_t=ZP-95ZSDLDRyyF- YouTube: https://youtube.com/@jjfeds?si=bX8_ii-GccsfXHN8Organizations, resources and citations referenced:Bayer: https://www.bayer.com/en/National Institutes of Health (NIH): https://www.nih.gov/U.S. Food and Drug Administration: https://www.fda.gov/Jennifer Doudna: https://vcresearch.berkeley.edu/faculty/jennifer-doudnaThe content shared in this episode is for informational purposes only and does not constitute medical, financial, or investment advice. Please seek guidance from your own qualified professionals before making decisions.Timestamps(00:00) Welcome Jessica Federer(00:50) Why Jessica cares deeply about women's health(02:10) Why 1993 was a turning point in clinical trials(04:33) NIH rules requiring women in funded research(08:28) Why women spend more years in poorer health(12:08) Mammograms, heart disease, and missed opportunities(15:36) Why cancer treatment may look barbaric in hindsight(18:53) Why top talent is moving into women's health(21:13) Autoimmune disease and the need for better systems(25:29) The next frontier: brain health and hormone scienceAbout Our Guest: Jessica Federer is a trailblazer and market builder. She was the first female chief digital Officer in the global pharmaceutical industry. She now sits on public and private boards, convenes the Health of Women Investor Summit and is the managing director of the Women's Health Fund. She also serves on the Yale IRB and the Yale Blavatnik Fund advisory.About Sharon: Sharon Kedar is a co-founder and partner at Northpond Ventures, a multi-billion-dollar science-driven venture capital firm. Her extensive career includes leadership roles at Sands Capital and McKinsey & Company, and she is a published author on personal finance. As the host of the Innovate and Elevate podcast, she passionately advocates for menopause care and HRT (hormone replacement therapy), challenging the silence around human health XX (also known as women's health). She aims to help women navigate midlife and achieve longevity by aging with power. Sharon holds an MBA from Harvard Business School and is a CFA charter holder. She lives in the Washington, DC area with her husband, Greg, their three kids, and their dog Bo.This podcast is produced by Brave Moon Podcasts: https://www.bravemoonpodcasts.com/

Crispr's ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message.In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe's engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose LNP delivery are essential to treating patients safely. They also explore Scribe's partnerships with Sanofi and Lilly, the company's cardiometabolic-first strategy co-developed with Dr. Jennifer Doudna, and Oakes' conviction that genetic medicines can fundamentally reshape healthspan and the future of preventive cardiovascular care.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Aurora Therapeutics quiere escalar terapias Crispr personalizadas para enfermedades raras usando una nueva ruta regulatoriaPor Félix Riaño @LocutorCoEn Estados Unidos, un bebé llamado KJ recibió un tratamiento de edición genética hecho para su caso, y los médicos creen que le salvó la vida. Ese detalle suena a ciencia ficción, pero está pasando ya: un equipo diseñó una terapia personalizada en unos seis meses, para corregir una mutación rara que le estaba causando una acumulación peligrosa de amonio en su cuerpo. KJ salió del hospital en junio.Ahora, la pregunta es otra: ¿esto se puede repetir para más personas, sin que cada paciente tenga que esperar años? Ahí entra Aurora Therapeutics, una nueva empresa cofundada por Jennifer Doudna, una de las científicas detrás de Crispr y ganadora del Nobel en 2020. Aurora quiere convertir estos “tratamientos a la medida” en algo más común para enfermedades raras. ¿El atajo? Una ruta nueva en la FDA, la agencia que autoriza medicamentos en Estados Unidos.)Y aquí viene el giro: si el regulador acepta aprobar terapias con datos de pocas personas, ¿cómo se protege la seguridad cuando el tratamiento es distinto en cada paciente?Suena rápido, pero el riesgo es editar donde no tocaPlanteamiento descriptivo (más de 100 palabras)Vamos por partes y sin tecnicismos raros. Crispr es una familia de herramientas que ayuda a “apuntar” a un lugar específico del material genético para hacer un cambio. En el caso de terapias personalizadas, la idea es sencilla de decir y difícil de ejecutar: si una enfermedad viene de una mutación concreta, se intenta corregir esa mutación concreta.El problema es que muchas enfermedades raras tienen poquísimos pacientes. Entonces, hacer ensayos clínicos grandes, con cientos o miles de personas, se vuelve casi imposible. Y ahí aparece un debate enorme: ¿cómo apruebas un tratamiento cuando no puedes reunir tanta gente para probarlo?Aurora Therapeutics dice que va a apoyarse en una ruta nueva de la FDA llamada “plausible mechanism pathway”, que busca aprobar terapias personalizadas para enfermedades raras y graves cuando un ensayo grande no es realista.Aquí está la tensión: la promesa de “medicina a la carta” choca con la realidad de la seguridad y la evidencia. En medicina, normalmente se exigen estudios con muchos pacientes para saber dos cosas: si funciona, y si es seguro. En enfermedades raras, ese estándar clásico se vuelve una pared: no hay suficientes personas para llenar un estudio grande, y cada mutación puede ser diferente.Aurora quiere empezar por una enfermedad metabólica llamada fenilcetonuria, o PKU, que se detecta con tamizaje al nacer. La PKU puede llevar a niveles tóxicos de fenilalanina en sangre y, sin manejo temprano, afectar el desarrollo del cerebro. En Estados Unidos se habla de unas 13.500 personas viviendo con PKU. El reto extra: hay más de mil mutaciones distintas que pueden causarla. (WIRED)Entonces, aunque el “motor” de la terapia sea el mismo, el “destino” cambia. Y cuando cambias el destino, también cambian los riesgos: el editor podría actuar donde no debe, lo que se conoce como efectos fuera del objetivo. (La apuesta de Aurora se apoya en una idea de plataforma. Es decir: mantener el mismo proceso de diseño y fabricación, y cambiar una pieza que guía al editor hacia la mutación correcta. En el caso de KJ, la guía se diseñó para su mutación exacta, por eso su tratamiento era para él y para nadie más.Con PKU, Aurora quiere hacer “versiones” que cambien esa guía, para cubrir muchas mutaciones sin tener que empezar desde cero con un proceso regulatorio eterno cada vez. Y aquí la nueva ruta de la FDA es el centro del plan: en el artículo de la New England Journal of Medicine, los autores describen que, si un fabricante muestra éxito en varios pacientes consecutivos con terapias personalizadas relacionadas, la FDA podría avanzar hacia una autorización de comercialización del “producto”, usando esa experiencia para acelerar aprobaciones similares basadas en la misma tecnología.¿Y el “cinturón de seguridad” de todo esto? La ciencia está empujando en paralelo herramientas para controlar a Crispr, como anti-CRISPR diseñados con ayuda de inteligencia artificial, que funcionan como apagadores para que el editor no se quede activo más tiempo del debido. Un estudio en Nature Chemical Biology publicado el 26 de enero de 2026 describe el diseño “de novo” de inhibidores potentes para sistemas tipo Cas13, usando enfoques de diseño de proteínas guiados por IA.Vale la pena entender dos historias que se están juntando aquí: regulación y control tecnológico. Por el lado regulatorio, Reuters contó que la FDA presentó esta ruta de “mecanismo plausible” como una forma de permitir acceso más rápido a terapias para enfermedades extremadamente raras y graves, con aprobación basada en datos de pocos pacientes, y con seguimiento posterior usando evidencia del mundo real para confirmar beneficios y vigilar seguridad. Esa última parte es importante, porque no se trata de “aprobar y ya”, se trata de aprobar con condiciones y vigilancia fuerte. (Reuters)Por el lado tecnológico, el tema de los “apagadores” está creciendo porque la medicina no quiere un editor encendido sin control. Phys.org resume el problema así: aunque Crispr puede ser muy preciso, hay riesgos cuando el sistema actúa fuera del objetivo, y encontrar inhibidores naturales ha sido lento; por eso se explora el diseño con IA para crear inhibidores que funcionen como freno.Y aquí hay un matiz que me parece fascinante para contarlo en Flash Diario: la carrera ya no es solo “editar mejor”. También es “editar y poder detenerlo a tiempo”. Si Aurora logra una plataforma repetible y, a la vez, la ciencia logra controles más finos, la conversación cambia: pasamos de casos heroicos aislados, como el de KJ, a un modelo donde más familias podrían tener una opción realista.Pero queda una pregunta enorme para 2026: ¿cómo se diseña un sistema que sea rápido, personalizado y también verificable, cuando cada paciente es un mundo distinto?Aurora Therapeutics, con Jennifer Doudna, quiere llevar la edición genética personalizada a más pacientes con enfermedades raras, usando una ruta nueva de la FDA. La promesa es velocidad y acceso; el reto es seguridad y evidencia cuando cada terapia cambia. Quiero leerte: ¿te emociona o te preocupa este camino? Sigue Flash Diario en Spotify.Bibliografía WiredReutersNew England Journal of MedicineNature Chemical BiologyPhys.orgBioPharma DiveConviértete en un supporter de este podcast: https://www.spreaker.com/podcast/flash-diario-de-el-siglo-21-es-hoy--5835407/support.Apoya el Flash Diario y escúchalo sin publicidad en el Club de Supporters. 

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech! Elise Hu, Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey got together to share the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech!Elise Hu of TED Talks Daily hosted a conversation with Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey, where they discussed the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

What is the greatest sentence ever written? According to Walter Isaacson — former editor of Time, ex-CEO of CNN, and the acclaimed biographer of Elon Musk, Steve Jobs, Benjamin Franklin, and Jennifer Doudna — it's this: “We hold these truths to be self-evident, that all men are created equal, that they are endowed by their Creator with certain unalienable Rights, that among these are Life, Liberty and the pursuit of Happiness.” Yes, it's eloquent, but more than that, it gave the United States a mission statement, one that we are still striving — fitfully, imperfectly — to meet. Walter's new book, The Greatest Sentence Ever Written, unpacks that mission statement: how it came to be written, what it meant to the founders, and why it matters today. We're pleased to announce that we've chosen it as our latest selection for the Next Big Idea Club. That means current members will receive a copy in the mail any day now, along with a digital reading guide, the opportunity to discuss the book with fellow members in our WhatsApp community, and an exclusive invitation to a live Q&A with Walter in December. If you're not already a member, sign up today at nextbigideaclub.com. And if you use the code PODCAST at checkout, we'll take 20% off your order and send you a signed copy of the book. Learn more about your ad choices. Visit megaphone.fm/adchoices

What can today's biotech innovators learn from the greatest thinkers in history? In this special episode, we're bringing you a live recording from BIO on the BAYOU featuring a fireside chat between Elaine Hamm, PhD, and Walter Isaacson — renowned biographer of Steve Jobs, Jennifer Doudna, Leonardo da Vinci, Albert Einstein, and other groundbreaking innovators. Together, they explore the power of curiosity, resilience, and imagination in shaping scientific discovery. From the origins of creativity to the ethical challenges of AI and gene editing, this conversation shines a light on the shared traits that drive humanity's boldest breakthroughs. In this episode, you'll learn: Why history's greatest innovators were powered by relentless curiosity — not just intellect. What resilience looks like across centuries, from Leonardo da Vinci to modern-day misfits shaping the future. How scientists, universities, and the public can rebuild trust, communicate science better, and rekindle a shared sense of wonder. Tune in for an inspiring conversation that blends science, storytelling, and the timeless human drive to explore the unknown — straight from the BIO on the BAYOU stage. Links: Connect with Walter Isaacson and check out his new book The Greatest Sentence Ever Written. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

À l'heure de l'intelligence artificielle, le transhumanisme, qui prône l'usage des sciences afin d'améliorer la condition humaine par l'augmentation de ses capacités physiques et mentales, se développe. En 2012, les chercheuses Emmanuelle Charpentier et Jennifer Doudna, prix Nobel de chimie 2020, ont créé un système de modification du génome humain, rapide et peu coûteux. Leur technique, appelée CRISPR-Cas9, a été créée dans le but d'aider à lutter contre les maladies génétiques. Mais derrière la prouesse d'une telle technologie se sont des questions éthiques reviennent. D'où vient l'eugénisme ? Pourquoi parle-t-on d'eugénisme positif ? Pourquoi ce concept est-il d'actualité ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Samuel Lumbroso. Première diffusion : juillet 2023 À écouter aussi : ⁠Qu'est-ce que le racisme environnemental ?⁠ ⁠Quel est ce mouvement qui fait participer les amateurs à la science ?⁠ ⁠Que risque-t-on à devenir volontaire pour la science ?⁠ Retrouvez tous les épisodes de ⁠"Maintenant vous savez".⁠ Suivez Bababam sur ⁠Instagram⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the four years since the book’s publication, CRISPR has revolutionized the world of medical treatments and possibilities. But our world has changed drastically, too. As AI’s impact grows, U.S scientists are facing funding cuts like never before. For our final episode, we bring you a live conversation between Walter Isaacson and Jennifer Doudna at the New Orleans Book Festival. In her own words, you’ll hear Doudna explain how CRISPR blossomed from an idea to a phenomenon, and the challenges scientists faces in this politically fraught moment.See omnystudio.com/listener for privacy information.

As the gene editing field kept growing, so did the dangers. Back in 2018, Jennifer Doudna received an email from a Chinese scientist claiming that he had genetically edited two twin babies. The news reverberated across the world and made Doudna and her colleagues urgently consider the implications of what their discovery could mean for humanity. Walter Isaacson sits down with Evan and tells him why the field has always been ripe with ethical questions, and how the COVID-19 pandemic pushed researchers to recalibrate their priorities.See omnystudio.com/listener for privacy information.

This week, we’re bringing you the first episode of Season 3 of the podcast ON CRISPR. Walter Isaacson — the bestselling biographer behind Musk, Einstein and Steve Jobs – and journalist Evan Ratliff (Shell Game, Mastermind, Longform) take a behind-the-scenes look at the story of Jennifer Doudna, one of the scientific pioneers behind the gene editing software, CRISPR. In this episode, Evan sits down with Walter Isaacson to discuss Doudna’s upbringing, the history of DNA’s discovery and gene editing, and Baby KJ, a CRISPR patient who represents a milestone for both researchers and patients.See omnystudio.com/listener for privacy information.

Jennifer Doudna thought she had won the race. She thought she had beaten out all scientific competitors when she and her co-author had shocked the world with their groundbreaking technology for gene editing. But turned out, the race had just gotten fiercer. Walter Isaacson sits down with Evan to talk about how one of the most cutthroat scientific competitions in biotech got started around one goal — making CRISPR work for humans, and getting the credit for it.See omnystudio.com/listener for privacy information.

Earlier this year, when the world learned the news of baby KJ successfully undergoing the first personalized genetic treatment, it represented a milestone for researchers and patients. But behind this scientific feat there’s the story of the technology that made it possible, CRISPR, and one of the key pioneers behind it — Jennifer Doudna. Evan sits down with Walter Isaacson to understand how Doudna’s upbringing in Hilo, Hawaii influenced her trajectory as a gene editing scientist. And how the history of gene editing might have started with understanding DNA, but soon after, it became clear the real secret lay with its underrated sibling molecule, RNA.See omnystudio.com/listener for privacy information.

Walter Isaacson - bestselling biographer behind Musk, Einstein and Steve Jobs - in conversation with Evan Ratliff brings you behind the scenes of The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race. The story of the third great technological revolution in modern times. See omnystudio.com/listener for privacy information.

For UC Berkeley's Jennifer Doudna, the revolutionary discovery of CRISPR-Cas9 gene editing began 15 years ago with a meeting at the campus's Free Speech Movement Cafe. “This is a quintessential story about Berkeley,” begins Doudna, a professor of molecular and cell biology and of chemistry, in a lecture she gave on campus in April. “The research that I'll talk about today wouldn't have happened … if I had been working anywhere else. And that's because we have a really collaborative environment on our campus.”At the cafe, Doudna listened while a Berkeley colleague described a possible adaptive immune system in bacteria that helps them fight off viral infection. Doudna's lab went on to research the molecules involved, discovering a pathway that allows bacteria to "learn" about viruses, store the information and use it for protection.The scientists realized this same system could be used to trigger DNA repair in plant, animal and human cells, effectively allowing them to "rewrite the code of life." The seminal paper on CRISPR was published in 2012 by Doudna and her key collaborator, French microbiologist Emmanuelle Charpentier. The pair went on to win the Nobel Prize in Chemistry in 2020.In this Berkeley Talks episode, Doudna discusses how CRISPR can be used to correct disease-causing genetic mutations, the impact that it's already having on people's lives and where she sees the technology going in the future. “We're in an era of programmable genome editing,” she says. “It's really exciting to see all the possible applications of this. We know that it can be safe and effective to treat and even to potentially cure human disease, and we need to continue to advance the technology so that it can be deployed more widely.”Not only will that require continual activity on the science and technology front, she adds, but also in developing appropriate guidelines and regulations to ensure that CRISPR's applications move forward responsibly. Doudna's talk took place on April 4 as part of Brilliance of Berkeley, a course offered every spring by the College of Letters and Science that celebrates the campus's exceptional faculty and their accomplishments. Each week, students listen to two guest lectures by top Berkeley scholars from an array of fields, followed by a Q&A. Watch the video on the Brilliance of Berkeley YouTube page. Listen to the episode and read the transcript on UC Berkeley News (news.berkeley.edu/podcasts/berkeley-talks).Music by HoliznaCC0.Photo by Glenn Ramit/IGI. Hosted on Acast. See acast.com/privacy for more information.

As AI infiltrates every aspect of our lives, who are some of the people behind this huge inflection point? In this special three-part series, you'll hear from the people predicting and shaping our tech future. Host Manoush Zomorodi reports on the latest and revisits her favorite conversations with the minds crafting the digital world we live in today: what they've gotten right — and wrong — and where they think we're headed next. Part 3 features biochemist Jennifer Doudna, neurologist Tom Oxley and legal scholar Nita Farahany.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Please enjoy this re-release of a past episode of For the Ages. New episodes will return Fall 2025. Bestselling author Walter Isaacson, in conversation with David M. Rubenstein, discusses the life and work of the Nobel Prize-winning Jennifer Doudna who, with her collaborators, created a DNA-editing tool with the power to revolutionize human health. Recorded on  February 19, 2021 

Eric Topol (00:05):Hello, it's Eric Topol from Ground Truths, and I've got some really exciting stuff to talk to you about today. And it's about the announcement for a new Center for pediatric CRISPR Cures. And I'm delight to introduce doctors Jennifer Doudna and Priscilla Chan. And so, first let me say this is amazing to see this thing going forward. It's an outgrowth of a New England Journal paper and monumental report on CRISPR in May. [See the below post for more context]Let me introduce first, Dr. Doudna. Jennifer is the Li Ka Shing Chancellor's Chair and a Professor in the departments of chemistry and of molecular and cell biology at the University of California Berkeley. She's also the subject of this book, one of my favorite books of all time, the Code Breaker. And as you know, the 2020 Nobel Prize laureate for her work in CRISPR-Cas9 genome editing, and she founded the Innovative Genomics Institute (IGI) back 10 years ago. So Jennifer, welcome.Jennifer Doudna (01:08):Thank you, Eric. Great to be here.Eric Topol (01:10):And now Dr. Priscilla Chan, who is the co-founder of the Chan Zuckerberg Initiative (CZI) that also was started back in 2015. So here we are, a decade later, these two leaders. She is a pediatrician having trained at UCSF and is committed to the initiative which has as its mission statement, “to make it possible to cure, prevent, and manage all diseases in this century.” So today we're going to talk about a step closer to that. Welcome, Priscilla.Priscilla Chan (01:44):Thank you. Thanks for having me.Eric Topol (01:46):Alright, so I thought we'd start off by, how did you two get together? Have you known each other for over this past decade since you both got all your things going?Jennifer Doudna (01:56):Yes, we have. We've known each other for a while. And of course, I've admired the progress at the CZI on fundamental science. I was an advisor very early on and I think actually that's how we got to know each other. Right, Priscilla?Priscilla Chan (02:11):Yeah, that's right. We got to know each other then. And we've been crisscrossing paths. And I personally remember the day you won the Nobel Prize. It was in the heart of the pandemic and a lot of celebrations were happening over Zoom. And I grabbed my then 5-year-old and got onto the UCSF celebration and I was like, look, this is happening. And it was really cool for me and for my daughter.Eric Topol (02:46):Well, it's pretty remarkable convergence leading up to today's announcement, but I know Priscilla, that you've been active in this rare disease space, you've had at CZI a Rare As One Project. Maybe you could tell us a bit about that.Priscilla Chan (03:01):Yeah, so at CZI, we work on basic science research, and I think that often surprises people because they know that I'm a pediatrician. And so, they often think, oh, you must work in healthcare or healthcare delivery. And we've actually chosen very intentionally to work in basic science research. In part because my training as a pediatrician at UCSF. As you both know, UCSF is a tertiary coronary care center where we see very unusual and rare cases of pediatric presentations. And it was there where I learned how little we knew about rare diseases and diseases in general and how powerful patients were. And that research was the pipeline for hope and for new discoveries for these families that often otherwise don't have very much access to treatments or cures. They have a PDF that maybe describes what their child has. And so, I decided to invest in basic science through CZI, but always saw the power of bringing rare disease patient cohorts. One, because if you've ever met a parent of a child with rare disease, they are a force to be reckoned with. Two, they can make research so much better due to their insights as patients and patient advocates. And I think they close the distance between basic science and impact in patients. And so, we've been working on that since 2019 and has been a passion of ours.Eric Topol (04:40):Wow, that's great. Now Jennifer, this IGI that you founded a decade ago, it's doing all kinds of things that are even well beyond rare diseases. We recently spoke, I know on Ground Truths about things as diverse as editing the gut microbiome in asthma and potentially someday Alzheimer's. But here you were very much involved at IGI with the baby KJ Muldoon. Maybe you could take us through this because this is such an extraordinary advance in the whole CRISPR Cures story.Jennifer Doudna (05:18):Yes, Eric. It's a very exciting story and we're very, very proud of the teamwork that went into making it possible to cure baby KJ of his very rare disease. And in brief, the story began back in August of last year when he was born with a metabolic disorder that prevented him from digesting protein, it's called a urea cycle disorder and rare, but extremely severe. And to the point where he was in the ICU and facing a very, very difficult prognosis. And so, fortunately his clinical team at Children's Hospital of Philadelphia (CHOP) reached out to Fyodor Urnov, who is the Director of Translational Medicine at the IGI here in the Bay Area. They teamed up and realized that they could quickly diagnose that child because we had an IRB approved here at the IGI that allowed us to collect patient samples and do diagnosis. So that was done.Jennifer Doudna (06:26):We created an off-the-shelf CRISPR therapy that would be targeted to the exact mutation that caused that young boy's disease. And then we worked with the FDA in Washington to make sure that we could very safely proceed with testing of that therapy initially in the lab and then ultimately in two different animal models. And then we opened a clinical trial that allowed that boy to be enrolled with, of course his parents' approval and for him to be dosed and the result was spectacular. And in fact, he was released from the hospital recently as a happy, healthy child, gaining lots of weight and looking very chunky. So it's really exciting.Eric Topol (07:16):It's so amazing. I don't think people necessarily grasp this. This timeline [see above] that we'll post with this is just mind boggling how you could, as you said Jennifer, in about six months to go from the birth and sequencing through cell specific cultures with the genome mutations through multiple experimental models with non-human primates even, looking at off-target effects, through the multiple FDA reviews and then dosing, cumulatively three dosing to save this baby's life. It really just amazing. Now that is a template. And before we go to this new Center, I just wanted to also mention not just the timeline of compression, which is unimaginable and the partnership that you've had at IGI with I guess Danaher to help manufacture, which is just another part of the story. But also the fact that you're not just even with CRISPR 1.0 as being used in approvals previously for sickle cell and β-thalassemia, but now we're talking about base editing in vivo in the body using mRNA delivery. So maybe you could comment on that, Jennifer.Jennifer Doudna (08:38):Yeah, very good point. So yeah, we used a version of CRISPR that was created by David Liu at the Broad Institute and published and available. And so, it was possible to create that, again, targeted to the exact mutation that caused baby KJ's disease. And fortunately, there was also an off-the-shelf way to deliver it because we had access to lipid nanoparticles that were developed for other purposes including vaccinations. And the type of disease that KJ suffered from is one that is treatable by editing cells in the liver, which is where the lipid nanoparticle naturally goes. So there were definitely some serendipity here, but it was amazing how all of these pieces were available. We just had to pull them together to create this therapy.Eric Topol (09:30):Yeah, no, it is amazing. So that I think is a great substrate for starting a new Center. And so, maybe back to you Priscilla, as to what your vision was when working with Jennifer and IGI to go through with this.Priscilla Chan (09:45):I think the thing that's incredibly exciting, you mentioned that at CZI our mission is to cure, prevent, and manage all disease. And when we talked about this 10 years ago, it felt like this far off idea, but every day it seems closer and closer. And I think the part that's super exciting about this is the direct connection between the basic science that's happening in CRISPR and the molecular and down to the nucleotide understanding of these mutations and the ability to correct them. And I think many of us, our imaginations have included this possibility, but it's very exciting that it has happened with baby KJ and CHOP. And we need to be able to do the work to understand how we can treat more patients this way, how to understand the obstacles, unblock them, streamline the process, bring down the cost, so that we better understand this pathway for treatment, as well as to increasingly democratize access to this type of platform. And so, our hope is to be able to do that. Take the work and inspiration that IGI and the team at CHOP have done and continue to push forward and to look at more cases, look at more organ systems. We're going to be looking in addition to the liver, at the bone marrow and the immune system.Priscilla Chan (11:17):And to be able to really work through more of the steps so that we can bring this to more families and patients.Eric Topol (11:30):Yeah, well it's pretty remarkable because here you have incurable ultra-rare diseases. If you can help these babies, just think of what this could do in a much broader context. I mean there a lot of common diseases have their roots with some of these very rare ones. So how do you see going forward, Jennifer, as to where you UC Berkeley, Gladstone, UCSF. I'm envious of you all up there in Northern California I have to say, will pull this off. How will you get the first similar case to KJ Muldoon going forward?Jennifer Doudna (12:13):Right. Well, IGI is a joint institute, as you probably know, Eric. So we were founded 10 years ago as a joint institute between UC Berkeley and UCSF. And now we have a third campus partner, UC Davis and we have the Gladstone Institute. So we've got an extraordinary group of clinicians and researchers that are coming together for this project and the Center to make it a success. We are building a clinical team at UCSF. We have several extraordinary leaders including Jennifer Puck and Chris Dvorak, and they are both going to be involved in identifying patients that could be enrolled in this program based on their diagnosis. And we will have a clinical advisory group that will help with that as well. So we'll be vetting patients probably right after we announce this, we're going to be looking to start enrolling people who might need this type of help.Eric Topol (13:18):Do you think it's possible to go any faster right now than the six months that it took for KJ?Jennifer Doudna (13:26):I think it could be. And here's the reason. There's a very interesting possibility that because of the type of technology that we're talking about with CRISPR, which fundamentally, and you and I have talked about this previously on your other podcast. But we've talked about the fact that it's a programmable technology and that means that we can change one aspect of it, one piece of it, which is a piece of a molecule called RNA that's able to direct CRISPR to the right sequence where we want to do editing and not change anything else about it. The protein, the CRISPR protein stays the same, the delivery vehicle stays the same, everything else stays the same. And so, we're working right now with FDA to get a platform designation for CRISPR that might allow streamlining of the testing process in some cases. So it'll obviously come down to the details of the disease, but we're hopeful that in the end it will be possible. And Priscilla and I have talked about this too, that as AI continues to advance and we get more and more information about rare diseases, we'll be able to predict accurately the effects of editing. And so, in some cases in the future it may be possible to streamline the testing process even further safely.Eric Topol (14:51):And I also would note, as you both know, well this administration is really keen on genome editing and they've had a joint announcement regarding their support. And in my discussions with the FDA commissioner, this is something they are very excited about. So the timing of the new Center for pediatric CRISPR Cures is aligned with the current administration, which is good to see. It's not always the case. Now going back, Priscilla, to your point that not just for the liver because delivery has been an issue of course, and we're going to try to get after a lot of these really rare diseases, it's going to go beyond there. So this is also an exciting new dimension of the Center, as you said, to go after the bone marrow for hematopoietic cells, perhaps other organs as well.Priscilla Chan (15:42):I mean what the expertise and feasibility, the immune system is going to be the next target. Jennifer Puck has been a pioneer in this work. She's the one who designed the newborn screen that will be the tool that picks up these patients as they are born. And I think the thing that's tremendous is the immune system, first of all is active in many, many diseases, not just these cases of children born with partial or absence of immune systems. And the course right now that these babies are left with is complete isolation and then a very long and arduous course of a bone marrow transplant with high morbidity and mortality. And even if after the transplant you have complications like graft versus host and immunosuppression. And so, the idea of being able to very specifically and with less the conditioning and morbidity and mortality of the treatment, being able to address this is incredible. And the implications for other diseases like blood cancers or other hematopoietic diseases, that's incredible. And that actually has an incredibly broad base of patients that can benefit from the learnings from these babies with severe combined immunodeficiencies.Eric Topol (17:10):Yeah, I think that goes back to a point earlier maybe to amplify in that previous CRISPR generation, it required outside the body work and it was extremely laborious and time consuming and obviously added much more to the expense because of hospitalization time. This is different. This is basically doing this inside the affected patient's body. And that is one of the biggest reasons why this is a big step forward and why we're so fortunate that your Center is moving forward. Maybe before we wrap up, you might want to comment, Jennifer on how you were able to bring in to build this platform, the manufacturing arm of it, because that seems to be yet another dimension that's helpful.Jennifer Doudna (18:01):Indeed, yes. And we were again fortunate with timing because you mentioned briefly that the IGI had set up a program with the Danaher Corporation back in January of last year. We call it our Beacon project. And it's focused on rare disease. And it's a really interesting kind of a unique partnership because Danaher is a manufacturing conglomerate. So they have companies that make molecules, they make proteins, they make RNA molecules, they make delivery molecules. And so, they were excited to be involved with us because they want to be a provider of these types of therapies in the future. And they can see the future of CRISPR is very exciting. It's expanding, growing area. And so, that agreement was in place already when the baby KJ case came to our attention. And so, what we're hoping to do with Danaher is again, work with them and their scientists to continue to ask, how can we reduce the cost of these therapies by reducing the cost of the molecules that are necessary, how to make them efficiently. We already, it's very interesting, Fyodor Urnov has toured their plant in North Dakota recently, and he found in talking to their engineers, there are a number of things that we can already see will be possible to do that are going to make the process of manufacturing these molecules faster and cheaper by a lot.Eric Topol (19:28):Wow.Jennifer Doudna (19:28):So it's a win-win for everybody. And so, we're really excited to do that in the context of this new Center.Eric Topol (19:36):Oh, that's phenomenal because some of these disorders you don't have that much time to work with before they could be brain or organ or vital tissue damage. So that's great to hear that. What you built here is the significance of it can't be under emphasized, I'll say because we have this May report of baby KJ, which could have been a one-off and it could have been years before we saw another cure of an ultra-rare disorder. And what you're doing here is insurance against that. You're going to have many more cracks at this. And I think this is the excitement about having a new dedicated Center. So just in closing, maybe some remarks from you Priscilla.Priscilla Chan (20:24):I just want to emphasize one point that's really exciting as we talk about these ultra-rare cases that they're often like one in a million. All these learnings actually help maximize the impact of lots of research across the sector that impacts actually everyone's health. And so, our learnings here from these patients that have very significant presentations that really can stand to benefit from any treatment is hopefully paving the way for many, many more of us to be able to live healthier, higher quality lives through basic science.Eric Topol (21:13):And over to you, Jennifer.Jennifer Doudna (21:15):Couldn't agree more. It's a really interesting moment. I think what we hope we are, is we're at sort of an inflection point where, as I mentioned earlier, all the pieces are in place to do this kind of therapeutic and we just need a team that will focus on doing it and pulling it together. And also learning from that process so that as Priscilla just said, we are ultimately able to use the same strategy for other diseases and potentially for diseases that affect lots of people. So it's exciting.Eric Topol (21:46):For sure. Now, if I could just sum up, this is now a decade past the origination of your work of CRISPR and how already at the first decade culminated in sickle cell disease treatment and β-thalassemia. Now we're into the second decade of CRISPR. And look what we've seen, something that was unimaginable until it actually happened and was reported just a little over a month ago. Now going back to Priscilla's point, we're talking about thousands of different rare Mendelian genomic disorders, thousands of them. And if you add them all up of rare diseases, we're talking about hundreds of millions of people affected around the world. So this is a foray into something much bigger, no less the fact that some of these rare mutations are shared by common diseases and approaches. So this really big stuff, congratulations to both of you and your organizations, the Innovative Genomics Institute and the Chan Zuckerberg Initiative for taking this on. We'll be following it with very deep interest, thank you.****************************************************Thanks for listening, reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.Thanks to Scripps Research, and my producer, Jessica Nguyen, and Sinjun Balabanoff for video/audio support.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

The creation of a landmark gene editing drug used to treat a baby with a rare genetic mutation which could help transform personalized medicine. Blood tests showed baby KJ had sky-high levels of ammonia, a toxic substance the body usually expels. The root cause was his genes - or more particularly a specific gene mutation. The race was on to try and treat him before his condition took a firm hold. His doctors came up with a radical solution - for the first time ever, they designed and applied a gene-editing drug in record time, specifically for him. Have we seen breakthrough in preventing genetic diseases? With Fyodor Urnov, a professor in the Molecular and Cell Biology Department at the University of California, Virginijus Šikšnys professor at the Life Science Center of Vilnius University, Waseem Qasim from the UCL Institute of Child Health in Great Ormond Street Hospital in London and Jennifer Doudna, Professor, University of California, Berkeley and founder of the Innovative Genomics Institute. Presented by Tanya Beckett. Produced by Bob Howard. Researched by Mauve Schaffer Edited by Tara McDermott.

Billionaire tech titan Elon Musk's time as a “special government employee” is coming to an end, but the DOGE team at the Defense Department will soon have greater influence on Pentagon contracting. Since President Donald Trump began his second term in January, Musk has spearheaded the Department of Government Efficiency's push across the federal government to find “waste, fraud and abuse,” slash certain types of spending and cut the workforce. A DOGE team was set up at the Pentagon — as well as other federal agencies — to implement those efforts. Musk wrote Wednesday night in a post on X that his time as a special government employee was coming to an end but: “The @DOGE mission will only strengthen over time as it becomes a way of life throughout the government.” In a sign that DOGE's influence will continue at the Pentagon, Secretary of Defense Pete Hegseth issued a new directive this week giving those personnel more oversight of contracting efforts. Hegseth wrote in a May 27 memo to senior Pentagon leadership, combatant commanders, and DOD agency and field activity directors that: “The Department of Defense (DoD) Department of Government Efficiency (DOGE) team will have the opportunity to provide input on all unclassified contracts. The Under Secretary of Defense for Acquisition and Sustainment (USD(A&S)), or its designee, will coordinate with DOGE to ensure that the opportunity for review of the Performance Work Statement/Statement of Work, accompanying estimates, deliverable descriptions, and requirements approval/validation documents, occurs when the requirements package is provided to a DoD contracting office to initiate a procurement or prior to the package being provided to a non-DoD assisting agency (e.g., General Services Administration).” In a video released Wednesday on X, Hegseth said the Pentagon had already saved more than $10 billion working with DOGE on previous efforts to review spending, including from a “line-by-line audit of over 50 contract vehicles.” Energy Secretary Chris Wright announced Thursday that the government would build a new supercomputer powered by NVIDIA chips and based at a department user facility at the Lawrence Berkeley National Laboratory. Officials said the supercomputer will be named Doudna after UC Berkeley scientist Jennifer Doudna, who co-invented CRISPR gene editing technology and won the Nobel Prize back in 2020. The Doudna supercomputer, which is geared toward high-performance computing and training artificial intelligence technology, will be based at the National Energy Research Scientific Computing Center. It is only the latest Energy Department project designed for the AI age: El Capitan, a supercomputer based at Lawrence Livermore National Laboratory and currently the world's fastest, is also designed with machine learning in mind, as is Frontier, a DOE supercomputer housed at the Oak Ridge National Laboratory in Tennessee. A spokesperson would not comment further on how the Doudna supercomputer's speeds might compare to other systems. Government supercomputing projects, including those focused on AI, are now supported by the same national laboratory system that incubated the Manhattan Project, which produced the world's first atomic weapons. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast  on Apple Podcasts, Soundcloud, Spotify and YouTube.

When someone we know or love starts to develop psychological issues, we don't often associate it with a form of dementia. However, this trait is one of the most common signs of frontotemporal dementia (FTD) — the most common neurodegenerative disease in people under the age of 65. In his new book, Mysteries of the Social Brain: Understanding Human Behavior Through Science, Dr. Bruce Miller highlights his experiences observing people with FTD and what they have taught him about what he calls the "social brain."Dr. Bruce Miller has been observing people with FTD for decades in the Memory and Aging Center at the University of San Francisco, where he is also Professor of Neurology and the Founding Director of the Global Brain Health Institute. He shares key insights on how to keep our "social brain" healthy and how it can even unlock our creative potential.

Byron Goo, CEO of Tea Chest Hawaiʻi, talks about how tariffs are affecting the tea trade; Jennifer Doudna, Nobel Laureate in Chemistry, discusses developments in gene-editing with CRISPR

AP's Lisa Dwyer reports on a new US supercomputer project.

Dana Foss and Ross Wilson are the cofounders of Editpep, a biotech startup focused on developing CRISPR-based therapeutics. They are using a proprietary peptide-based delivery platform that enables targeted delivery to specific cell types, particularly for hard-to-reach areas like the brain. While Dana Foss is the CEO, Ross Wilson is also an Assistant Adjunct Professor of Molecular and Cell Biology and also the Director of Therapeutic Delivery at the Innovative Genomics Institute at the University of California, Berkeley. He is one of those very few academics that co-founded a startup and is very active in building Editpep. Ross explains how he does it all so well! Dana was  previously a postdoc in Ross Wilson's lab, where she developed the technology. Ross was a postdoc in Nobel Laureate Jennifer Doudna's lab. Now he has his own lab and collaborates with Jennifer Doudna at the Innovative Genomics Institute.  In this episode of lab to startup, we will explore their initial decisions that lead to launching the startup; existing CRISPR delivery technologies, their challenges, and then do a deep dive into their delivery technology. opportunities,; fundraising efforts, and their future goals. Shownotes https://www.editpep.bio/ CRISPR Delivery problem and current solutions Existing solutions like AV, LNPs are mostly limited to mice Ribonucleoprotein, a complex of RNA and protein (RNP): Technology deep dive Outsiders bringing in fresh perspective Dana transitioning out of academia: working on a shared goal Hard to shepard the technology towards the patient by depending on a third party Self motivation and gumption: Ways to move technologies out of the lab Early stage co-founder chemistry Ross's innovative role being an academic and entrepreneur Fundraising journey Open mindedness to non-traditional investors Investors: Berkeley Skydeck,  Lindonlight Collective Filters for selecting investors Getting to market: Parallels from other delivery companies like Alnylam Counterintuitive decisions Future goals Connecting the dots

Join us in this episode of The SaaS CFO Podcast as we welcome Dov Gertz, CEO and co-founder of Converge Bio. With an impressive background in computer science and bioinformatics, Dov has contributed groundbreaking research in genome editing alongside Nobel Prize laureate Professor Jennifer Doudna. Currently, he leads Converge Bio, innovating at the crossroads of AI and biotech to enhance pharmaceutical R&D. Converge Bio is revolutionizing the biotech and pharma landscape with advanced AI solutions designed to expedite research and development processes. Dov shares insights into the company's focus on optimizing antibody design and protein manufacturing, as well as their tailored pricing models that cater to both large pharmas and smaller biotech firms. Discover how Converge Bio's early product market fit is driving demand and shaping the future of drug development. In this episode, Dov also sheds light on the company's strategic journey from inception in 2024 to raising $6 million in seed funding. He emphasizes the importance of a strong team and customer validation in building a successful startup. Tune in to explore the transformative potential of AI in life sciences and Converge Bio's mission to deliver better medications to patients worldwide. Show Notes: 00:00 Entrepreneurial Journey in Biotech 04:29 Pharma Belief Divide 09:11 Building a Successful Startup Team 09:51 Early Stage Startups: Team Focus Importance 13:18 Exploring Converged Bio's Journey Links: SaaS Fundraising Stories: https://www.thesaasnews.com/news/converge-bio-raises-5-5-million-in-seed-round Dov Gertz's LinkedIn: https://www.linkedin.com/in/dov-gertz-20612b145/ Converge Bio's LinkedIn: https://www.linkedin.com/company/converge-bio/ Converge Bio's Website: https://converge-bio.com/ To learn more about Ben check out the links below: Subscribe to Ben's daily metrics newsletter: https://saasmetricsschool.beehiiv.com/subscribe Subscribe to Ben's SaaS newsletter: https://mailchi.mp/df1db6bf8bca/the-saas-cfo-sign-up-landing-page SaaS Metrics courses here: https://www.thesaasacademy.com/ Join Ben's SaaS community here: https://www.thesaasacademy.com/offers/ivNjwYDx/checkout Follow Ben on LinkedIn: https://www.linkedin.com/in/benrmurray

À l'heure de l'intelligence artificielle, le transhumanisme, qui prône l'usage des sciences afin d'améliorer la condition humaine par l'augmentation de ses capacités physiques et mentales, se développe dans l'ombre. En 2012, les chercheuses Emmanuelle Charpentier et Jennifer Doudna, prix Nobel de chimie 2020, ont créé un système de modification du génome humain, rapide et peu coûteux. Leur technique, appelée CRISPR-Cas9, a été créée dans le but d'aider à lutter contre les maladies génétiques. Mais derrière la prouesse d'une telle technologie se sont des questions éthiques reviennent. En effet, les questionnement autour l'idéologie eugéniste reviennent sur de la scène, il s'agit de la sélection du patrimoine génétique des générations futures d'une population en fonction d'un cadre de choisi.  D'où vient l'eugénisme ? Pourquoi parle-t-on d'eugénisme positif ? Pourquoi ce concept est-il d'actualité ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Samuel Lumbroso. À écouter aussi : Qu'est-ce que le racisme environnemental ? Quel est ce mouvement qui fait participer les amateurs à la science ? Que risque-t-on à devenir volontaire pour la science ? Retrouvez tous les épisodes de "Maintenant vous savez". Première diffusion le 14/07/23 Learn more about your ad choices. Visit megaphone.fm/adchoices

Jennifer Doudna changed the world. She didn't do it intentionally. She pursued her curiosity about the structure and functioning of RNA as a research scientist, one who had been trained by some of the most impactful geneticists at the time, including two Nobel laureates. In the process, however, she and her collaborators discovered a genetic tool that has dwarfed all others for its potential to change both the human condition, but also what it may mean to be human. I am referring of course to CRISPR, the tool that Jennifer Doudna and Emmanuelle Charpentier helped develop and for which they were awarded the Nobel Prize. In our in-depth conversation we covered the scientific origins of Jennifer's discoveries, and some of their possible implications. In a time when there is a misplaced notion that support for scientific research needs to be applied directly for certain goal-oriented activities, it is refreshing to have such a clear example of the benefits of fundamental research for our society, along with the need to prepare our minds for the possibilities of the future. It is exactly what the Origins Podcast, and the Origins Project Foundation are designed to highlight—the joy, benefits, and challenges of human intellectual inquiry for our society and our future. It was a pleasure and privilege to spend 90 minutes discussing these issues with this world-renowned biochemist and advocate for science. Our conversation was both a tutorial about modern genetics, and also an opportunity to discuss issues that society as a whole will have address as we come to grips with the new power of science in this century. With great power comes great responsibility, and I hope discussions such as the one I had with Jennifer will provoke and enlighten. Enjoy. As always, an ad-free video version of this podcast is also available to paid Critical Mass subscribers. Your subscriptions support the non-profit Origins Project Foundation, which produces the podcast. The audio version is available free on the Critical Mass site and on all podcast sites, and the video version will also be available on the Origins Project YouTube. Get full access to Critical Mass at lawrencekrauss.substack.com/subscribe

Join Professor Hannah Fry at the AI for Science Forum for a fascinating conversation with Google DeepMind CEO Demis Hassabis.  They explore how AI is revolutionizing scientific discovery, delving into topics like the nuclear pore complex, plastic-eating enzymes, quantum computing, and the surprising power of Turing machines. The episode also features a special 'ask me anything' session with Nobel Laureates Sir Paul Nurse, Jennifer Doudna, and John Jumper, who answer audience questions about the future of AI in science.Watch the episode here, and catch up on all of the sessions from the AI for Science Forum here.      Please subscribe on your preferred podcast platform. Want to share feedback? Why not leave a review? Have a suggestion for a guest that we should have on next? Leave us a comment on YouTube and stay tuned for future episodes.

Diving into a short story on scientist Jennifer Doudna and what I like to call the Obsession Test.Check out Walter Isaacson's book, The Code Breaker, for more on Doudna and how she is changing the world.-----“I'm someone who's thinking about science all the time. I'm always focused on what's cooking in the lab, the next experiment, or the bigger question to pursue. I was always obsessed with what my next experiment was going to be.”- Jennifer Doudna -----You can check support and stay connected belowWebsiteBook: Chasing Greatness: Timeless Stories on the Pursuit of Excellence  ApparelInstagramX

From robot helpers to smart body parts, the line between humans and machines is blurring. This hour, TED speakers design tech that enhances us without diminishing our humanity. Guests include robot choreographer and computer scientist Catie Cuan, engineer and biophysicist Hugh Herr, material scientist Anna Maria Coclite and biochemist Jennifer Doudna. TED Radio Hour+ subscribers now get access to bonus episodes, with more ideas from TED speakers and a behind the scenes look with our producers. A Plus subscription also lets you listen to regular episodes (like this one!) without sponsors. Sign-up at: plus.npr.org/tedLearn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Fareed examines two emerging technologies that are already changing life as we know it—CRISPR gene editing and artificial intelligence—in interviews with two women who pioneered them: UC Berkeley's Jennifer Doudna and Stanford's Fei-Fei Li. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Listen in to this informative episode with Pete O'Heeron, CEO of FibroBiologics, as we explore his  journey from a small, innovative town to the forefront of healthcare innovation.  Pete shares how his upbringing in a medically inclined family and a community rich with inventiveness influenced his career. Hear how Pete transitioned from pre-med to hospital administration due to unforeseen geopolitical events, ultimately finding his passion within the healthcare industry.Pete recounts his transformative experience at Christus, a multi-billion dollar hospital system, where his pivot from hospital administration to product development led to significant advancements in surgical instruments and an impressive return for shareholders. We delve into the revolutionary potential of fibroblasts, often overshadowed by stem cells, and their efficacy in regenerating tissue and treating chronic diseases. Pete explains how innovative techniques in fibrogenesis, such as applying pressure in low oxygen environments, can turn dermal fibroblasts into cartilage-type cells, opening new therapeutic avenues.We also cover the exciting advancements in fibroblast research and its applications across various medical fields. Highlighting the influence of Nobel Prize winners like Jim Allison and Jennifer Doudna, Pete discusses the promising results seen in wound care, multiple sclerosis, degenerative diseases, and more. With plans for upcoming clinical trials and commercialization strategies, Pete shares his admiration for influential figures like Elon Musk and reflects on the unique approaches to leadership in the biotech industry. Don't miss this engaging conversation filled with valuable insights into healthcare innovation and strategic partnerships.Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

You've probably heard of CRISPR, the revolutionary technology that allows us to edit the DNA in living organisms. Biochemist and 2023 Audacious Project grantee Jennifer Doudna earned the Nobel Prize for her groundbreaking work in this field — and now she's here to tell us about its next world-changing advancement. She explains how her team at the Innovative Genomics Institute is pioneering a brand new field of science — precision microbiome editing — that uses CRISPR in an effort to solve seemingly insurmountable problems like asthma, Alzheimer's and climate change. This ambitious idea is part of the Audacious Project, TED's initiative to inspire and fund global change.

For the longest time, when you thought about the most powerful person in the world, the person who probably came to mind was the president of the United States, the leader of the free world. But in 2023, the person who comes to mind for most people these days isn't an elected official at all. Instead, a lot of people picture a 52-year-old civilian who, through his own determination, ambition, and sheer will, has amassed an enormous amount of wealth—more than any other person on this planet—and also an enormous amount of influence over many of the most important industries in the world, especially as we look to the future. Elon Musk's biography is difficult to summarize, but that's exactly what our guest today, Walter Isaacson, has spent the past two and a half years doing: outlining Elon Musk's life to the tune of about 700 pages, in a new book simply titled Elon Musk. Isaacson is an award-winning biographer of luminaries including Henry Kissinger, Benjamin Franklin, Albert Einstein, Leonardo da Vinci, Steve Jobs, and Jennifer Doudna. But this recent undertaking has no doubt been his most complicated one to date. That's because the man he wrote about has a story that's very much still unfolding. In fact, when Walter Isaacson started writing the book, Musk hadn't even purchased Twitter yet.  One of the questions that underlies the entire biography is this: What does it mean for a single man to have so much singular power? And though Walter doesn't answer the question explicitly, we've all had a glimpse into exactly what it means for the world during this past month. Take, for example, how when Israel briefly cut off the internet inside of Gaza as part of their war strategy to eliminate Hamas, Elon announced that he was going to provide it himself through his company, Starlink. After widespread criticism, he posted an exploding head emoji. Then, when a commenter suggested that he must have felt pressure to provide the coverage, Elon simply responded, “yeah,” with a frowny face. Musk apparently then met with the head of Shin Bet, Israel's internal security service, and announced that he would, “double check with Israeli and U.S. security officials before enabling any connections.” The point, as my friend and writer Jacob Siegel put it, is that “non-state kingmakers are redefining the scope of warfare through direct intervention.” Of course, there's also Elon's newfound power over the information that all of us consume on X, Twitter's new brand. It's hard to imagine under Twitter's previous regime that we would have had access to the raw, brutally violent footage from Hamas's October 7 massacre. Elon's version of Twitter, which is less censorious than the previous guard, has allowed millions of people across the globe to see—with their own eyes—exactly what Hamas did. And yet, with those loosened rules, there's also so much genuine disinformation spread at a pace like never before. Scores of people, including elected officials like Congresswoman Ilhan Omar, are posting horrifying photos and videos of crying children from Gaza, when in reality they are photos and videos from Syria in 2013.  It has never been clearer that one man wields an enormous amount of influence over everything from social media to warfare. And the question is, should he? That's the theme of today's conversation.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The technology known as CRISPR is considered one of modern biology’s biggest breakthroughs. It allows scientists to edit genes, similar to how you cut and paste text in a word processor. More than a decade after pioneering CRISPR, Nobel laureate Jennifer Doudna of the University of California, Berkeley, is applying it to big problems, like chronic disease and climate change.Marketplace's Lily Jamali recently met up with Doudna at Berkeley’s Innovative Genomics Institute. It's a cluster of lab stations, researchers and very loud refrigerators where CRISPR is used to edit microbiomes.

The technology known as CRISPR is considered one of modern biology’s biggest breakthroughs. It allows scientists to edit genes, similar to how you cut and paste text in a word processor. More than a decade after pioneering CRISPR, Nobel laureate Jennifer Doudna of the University of California, Berkeley, is applying it to big problems, like chronic disease and climate change.Marketplace's Lily Jamali recently met up with Doudna at Berkeley’s Innovative Genomics Institute. It's a cluster of lab stations, researchers and very loud refrigerators where CRISPR is used to edit microbiomes.

You've probably heard of CRISPR, the revolutionary technology that allows us to edit the DNA in living organisms. Biochemist and 2023 Audacious Project grantee Jennifer Doudna earned the Nobel Prize for her groundbreaking work in this field -- and now she's here to tell us about its next world-changing advancement. She explains how her team at the Innovative Genomics Institute is pioneering a brand new field of science -- precision microbiome editing -- that uses CRISPR in an effort to solve seemingly insurmountable problems like asthma, Alzheimer's and climate change. (This ambitious idea is part of the Audacious Project, TED's initiative to inspire and fund global change.)

You've probably heard of CRISPR, the revolutionary technology that allows us to edit the DNA in living organisms. Biochemist and 2023 Audacious Project grantee Jennifer Doudna earned the Nobel Prize for her groundbreaking work in this field -- and now she's here to tell us about its next world-changing advancement. She explains how her team at the Innovative Genomics Institute is pioneering a brand new field of science -- precision microbiome editing -- that uses CRISPR in an effort to solve seemingly insurmountable problems like asthma, Alzheimer's and climate change. (This ambitious idea is part of the Audacious Project, TED's initiative to inspire and fund global change.)

Walter Isaacson is an author of biographies on Elon Musk, Steve Jobs, Einstein, Benjamin Franklin, Leonardo da Vinci, and many others. Please support this podcast by checking out our sponsors: - MasterClass: https://masterclass.com/lexpod to get 15% off - NetSuite: http://netsuite.com/lex to get free product tour - BetterHelp: https://betterhelp.com/lex to get 10% off - ExpressVPN: https://expressvpn.com/lexpod to get 3 months free - Shopify: https://shopify.com/lex to get $1 per month trial Transcript: https://lexfridman.com/walter-isaacson-transcript EPISODE LINKS: Walter's Twitter: https://twitter.com/WalterIsaacson Walter's Instagram: https://www.instagram.com/walter_isaacson Walter's Website: https://isaacson.tulane.edu Walter's Books: Elon Musk: https://amzn.to/48aWSZC The Code Breaker: https://amzn.to/3EAa0cU Leonardo da Vinci: https://amzn.to/3RlFICB The Innovators: https://amzn.to/45R8gs4 Steve Jobs: https://amzn.to/3P9Ak2B American Sketches: https://amzn.to/45LM4PN Einstein: https://amzn.to/3r6Ttu6 Benjamin Franklin: https://amzn.to/44NobWW Kissinger: https://amzn.to/3RdTA1u The Wise Men: https://amzn.to/45LQDJX PODCAST INFO: Podcast website: https://lexfridman.com/podcast Apple Podcasts: https://apple.co/2lwqZIr Spotify: https://spoti.fi/2nEwCF8 RSS: https://lexfridman.com/feed/podcast/ YouTube Full Episodes: https://youtube.com/lexfridman YouTube Clips: https://youtube.com/lexclips SUPPORT & CONNECT: - Check out the sponsors above, it's the best way to support this podcast - Support on Patreon: https://www.patreon.com/lexfridman - Twitter: https://twitter.com/lexfridman - Instagram: https://www.instagram.com/lexfridman - LinkedIn: https://www.linkedin.com/in/lexfridman - Facebook: https://www.facebook.com/lexfridman - Medium: https://medium.com/@lexfridman OUTLINE: Here's the timestamps for the episode. On some podcast players you should be able to click the timestamp to jump to that time. (00:00) - Introduction (10:42) - Difficult childhood (27:47) - Jennifer Doudna (30:44) - Einstein (36:02) - Tesla (53:07) - Elon Musk's humor (57:17) - Steve Jobs' cruelty (1:00:41) - Twitter (1:12:50) - Firing (1:15:35) - Hiring (1:24:38) - Time management (1:32:22) - Groups vs individuals (1:36:08) - Mortality (1:39:40) - How to write (2:00:38) - Love & relationships (2:05:33) - Advice for young people

Jennifer Doudna developed a method of genome editing along with her partner Emmanuelle Charpentier and together they won the Nobel Prize in Chemistry in 2020. Her unique journey from graduate student to Nobel prize winning scientist is chronicled by the biographer of geniuses, Walter Isaacson. His New York Times best-seller, The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race is available now.  See omnystudio.com/listener for privacy information.

Original broadcast date: January 7, 2022. New innovations in gene and stem cell technology have the power to shape ecosystems and even change humanity. This hour, TED speakers share the breakthroughs heralding the next scientific revolution. Guests include biochemist Jennifer Doudna, physicist and biotech entrepreneur Nabiha Saklayen and conservation innovator and biotech entrepreneur Ryan Phelan.TED Radio Hour+ subscribers now get access to bonus episodes, with more ideas from TED speakers and a behind the scenes look with our producers. A Plus subscription also lets you listen to regular episodes (like this one!) without ads. Sign-up at plus.npr.org/ted.